On Nov 18, 2022, Simcere Pharmaceutical Group donated 5 million RMB to the Jiangsu Provincial Charity Federation to support charitable public welfar...

Lung cancer is the most common cancer afflicting the people of China, with 828,000 new cases and 657,000 deaths each year, according to the Chinese Na...

Nanjing, China & Allschwil, Switzerland & – November 16, 2022Simcere Pharmaceutical Group Ltd (2096.HK, “Simcere”), an innovation and R&...

- Simcere launches first oncology trial in the US- SIM0235 (SIM1811-03 injection) is a humanized immunoglobu...